Ranbaxy Lipitor Settlement With Pfizer Could Double Indian Firm Sales
This article was originally published in PharmAsia News
Executive Summary
The patent suit settlement Pfizer against Ranbaxy Laboratories could mean sales by India's largest drug maker will double within the next three years. The settlement ended Pfizer's suit against Ranbaxy and its generic of the U.S. company's Lipitor (atorvastatin). Last year, Lipitor brought $12.7 billion in sales to Pfizer, so the settlement allowing Ranbaxy to market a generic ahead of the expiration date for the drug patent could earn the Indian drug maker $2 billion, more than the firm's $1.78 billion in sales last year. Ranbaxy is allowed to begin marketing its generic in Canada after Nov. 30, and in the U.S. after Nov. 30, 2011. (Click here for more
You may also be interested in...
Ranbaxy Forecasts Conservative Growth, Remains Silent On Atorvastatin Launch, U.S. FDA Action
MUMBAI - Daiichi-Sankyo controlled Ranbaxy Laboratories Ltd. took analysts in India by surprise with a forecast of a very conservative growth target that did not factor in any upside from a possible launch of a generic version of Lipitor (atorvastatin) in the U.S
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.